Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.
PLoS One
; 14(8): e0220644, 2019.
Article
in En
| MEDLINE
| ID: mdl-31390375
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoadjuvant Therapy
/
Triple Negative Breast Neoplasms
/
Furans
/
Ketones
Limits:
Adult
/
Female
/
Humans
Language:
En
Journal:
PLoS One
Year:
2019
Document type:
Article